Treatment of nosocomial infections in intensive care unit with colistin and polymyxin B
- 36 Downloads
To the editor,
We read with interest the article entitled “Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis” by Quintanilha et al. . The study provides valuable data regarding nephrotoxicity, as a known complication of polymyxins (polymyxin B and colistin).
The authors described patients in the neurosurgical, cardiovascular, or transplantation intensive care units (ICUs) who received colistin or polymyxin B for the treatment of documented nosocomial infections. Their results revealed that neither the incidence of nephrotoxicity nor the 30-day mortality rate differed significantly between the patients who received either colistin or polymyxin B. Additionally, they found that colistin was superior to polymyxin B in terms of pharmacoeconomic aspects.
The mean rate of nephrotoxicity with polymyxins was reported to be as high as 32% based on the Acute Kidney Injury Network (AKIN) criteria . Despite their...
Conflicts of interest
The authors declare that they have no conflict of interest.